Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study

Author:Bermel, Robert   Killestein, Joep   Berger, Thomas   Brochet, Bruno   Carroll, William   Freedman, Mark   Holmoy, Trygve   Karabudak, Rana   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Vollmer, Timothy   Buffels, Regine   Kadner, Karen   Bortolami, Oscar   Hartung, Hans-Peter   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.003  

Author Institution:Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Department of Neurology, Medical University of Vienna, Vienna, Austria, Vienna, Austria  University of Bordeaux, Bordeaux, France, Bordeaux, France  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, Ottawa, ON, Canada  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Centre d’Esclerosi Mútiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA , Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Toulon, France  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Department of Neurology, UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Dusseldorf, Germany  

Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

Author:Williams, Mitzi   Airas, Laura   Chitnis, Tanuja   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Dörner, Thomas   Loop, Brett   Ziehn, Marina   Willi, Roman   Kieseier, Bernd C.   Nikolaev, Ivan   Haemmerle, Sibylle   Zharkov, Artem   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Giménez-Arnau, Ana   Montalban, Xavier   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.015  

Author Institution:Joi Life Wellness Group, Atlanta, GA, USA, Atlanta, GA  Turku University Hospital and University, Finland, Turku, Finland  Brigham and Women's Hospital, Department of Neurology, Boston, MA, USA, Boston, MA  Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA, Baltimore, MD  Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, Hiroshima, Japan  University of Toronto, Toronto, Ontario, Canada, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin  DRFZ, Berlin, Germany, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA, USA, Cambridge, MA  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland  Department of Neurology, Heinrich-Heine University, Duesseldorf, Germany, Duesseldorf, Germany  Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany  Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany, Berlin, Germany  Department of Dermatology, Hospital del Mar - IMIM, Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  

12-Month Effectiveness and Tolerability of Brivaracetam in the Real-World: The International EXPERIENCE Pooled Analysis

Author:Villanueva, Vicente   D'Souza, Wendyl   Faught, Edward   Klein, Pavel   Reuber, Markus   Rosenow, Felix   Salas-Puig, Javier   Soto Insuga, Victor   Strzelczyk, Adam   Szaflarski, Jerzy P.   Besson, Herve   Daniels, Tony   Floricel, Florin   Laloyaux, Cedric   Sendersky, Veronica   Zhou, Sophia   Steinhoff, Bernhard J.   

Session Name:P11: Epilepsy/Clinical Neurophysiology (EEG): ASMs Clinical Trial 1  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P11.003  

Author Institution:Hospital Universitario y Politécnico La Fe, Valencia, Spain, Valencia, Spain  Department of Medicine, St Vincent’s Hospital Melbourne, The University of Melbourne, Melbourne, Australia, Melbourne, Australia  Emory Epilepsy Center, Atlanta, GA, USA, Atlanta, GA  Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA, Bethesda, MD  The University of Sheffield, Sheffield, UK, Sheffield, United Kingdom  Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Frankfurt, Germany, Frankfurt am Main, Germany  Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Pediatric Neurology, Hospital Universitario Infantil Niño Jesús, Madrid, Spain, Madrid, Spain  Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Frankfurt, Germany, Frankfurt, Germany  UAB Epilepsy Center, Birmingham, AL, USA, Birmingham, AL  UCB Pharma, Breda, Netherlands, Breda, Netherlands  UCB Pharma, Morrisville, NC, USA, Morrisville, NC  UCB Pharma, Monheim am Rhein, Germany, Monheim Am Rhein, Germany  UCB Pharma, Brussels, Belgium, Brussels, Belgium  Kork Epilepsy Center, Kehl-Kork and Medical Faculty, University of Freiburg, Freiburg, Germany, Kork, Germany  

Predicting MRI Changes in Patients with MS in the Absence of Acute Inflammation

Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: Second Interim Analysis of the Observational PEARL Study